Benefits of rituximab as a second-line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study - Centre de recherche en cancérologie Nantes-Angers Unité Mixte de Recherche 892 Inserm - 6299 CNRS Access content directly
Journal Articles British Journal of Haematology Year : 2017

Benefits of rituximab as a second-line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study

Helder Fernandes
Yves Bertrand
  • Function : Author
  • PersonId : 938340
Fabrice Monpoux
  • Function : Author
Alain Fisher
  • Function : Author
Fanny Fouissac
  • Function : Author
Philippe Vic
  • Function : Author
Yves Perel
  • Function : Author

Dates and versions

hal-02413031 , version 1 (16-12-2019)

Identifiers

Cite

Stephane Ducassou, Guy Leverger, Helder Fernandes, Hervé Chambost, Yves Bertrand, et al.. Benefits of rituximab as a second-line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study. British Journal of Haematology, 2017, 177 (5), pp.751-758. ⟨10.1111/bjh.14627⟩. ⟨hal-02413031⟩
29 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More